Program
vonoprazan
Also written as “TAK-438”, “Vonoprazan” and “Vonoprazan (Reference)”.
Its studies are mostly in Esophagitis · Stomach Ulcer · Gastroesophageal Reflux · Heartburn · Duodenal Ulcer, led by 5 companies.
Drug pageVonoprazan: every studyMany companies study it; this page follows only the 48 they lead. All 100 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 310 open or running | phase 4since Feb 8, 2016 | Sep 16, 2011 | none ahead |
| Phathom Pharmaceuticalsits history only | 142 open or running | phase 3since Oct 10, 2019 | Oct 10, 2019 | Oct 20, 2027phase 3 · NCT07752407 |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Nov 14, 2021 | Nov 14, 2021 | none ahead |
| Hanlim Pharm.its history only | 10 open or running | phase 1since Oct 14, 2024 | Oct 14, 2024 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Dec 9, 2025 | Dec 9, 2025 | none ahead |
Also a collaborator on its studies: Richmond Pharmacology.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Takeda only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Sep 16, 2011.
- Jun 26, 2012Phase 3 study in Erosive EsophagitisNCT01630746 · 19 enrolled · Japan
- Apr 24, 20142 phase 1 studiesNCT02123953, NCT02123927
- May 15, 20142 phase 1 studiesNCT02141711, NCT02141698
- Mar 9, 20152 phase 3 studies in Erosive EsophagitisNCT02388737, NCT02388724
- Feb 8, 2016Phase 4 study in EsophagitisNCT02679508 · 208 enrolled · Japan
- May 13, 2016Phase 1 study in Healthy VolunteersNCT02774902 · 16 enrolled
- Sep 2, 2016Phase 1 study in Helicobacter PyloriNCT02892409 · 30 enrolled · Korea, Republic of
- Nov 1, 2016Phase 3 study in Non-erosive Gastroesophageal Reflux DiseaseNCT02954848 · 484 enrolled · Japan
- Feb 8, 20172 phase 3 studiesNCT03050359, NCT03050307
- Mar 16, 2017Phase 1 study in Healthy ParticipantsNCT03085836 · 33 enrolled · China
- Apr 12, 2017Phase 4 study in Esophagitis, PepticNCT03116841 · 3 enrolled · Japan
- Jan 16, 2019Phase 1 study in Japanese Healthy Adult MaleNCT03808493 · 48 enrolled · Japan
- Dec 12, 2019Phase 3 study in Helicobacter PyloriNCT04198363 · 510 enrolled · China
- Feb 12, 2021Phase 1 study in Helicobacter PyloriNCT04753437 · 44 enrolled · China
TargetBeta
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esomeprazolerule | AstraZeneca | phase 4 | 129 |
| Rabeprazolerule | Eisai | phase 4 | 66 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
All 31 Takeda leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04753437Helicobacter Pylori · China | 1 | Completed | Sep 27, 2021 | 44 |
| NCT04198363Helicobacter Pylori · China | 3 | Completed | Nov 1, 2021 | 510 |
| NCT03808493Japanese Healthy Adult Male · Japan | 1 | Completed | Mar 12, 2019 | 48 |
| NCT03116841Esophagitis, Peptic · Japan | 4 | Completed | Dec 20, 2017 | 3 |
| NCT03085836Healthy Participants · China | 1 | Completed | Aug 17, 2017 | 33 |
| NCT03050359Duodenal Ulcer · China, Korea, Republic of, Philippines and more | 3 | Completed | Mar 19, 2019 | 533 |
| NCT03050307Stomach Ulcer · China, Korea, Republic of, Philippines and more | 3 | Completed | Feb 19, 2020 | 234 |
| NCT02954848Non-erosive Gastroesophageal Reflux Disease · Japan | 3 | Completed | Feb 25, 2018 | 484 |
| NCT02892409Helicobacter Pylori · Korea, Republic of | 1 | Completed | Apr 17, 2017 | 30 |
| NCT02774902Healthy Volunteers | 1 | Completed | Sep 2010 | 16 |
| NCT02679508Esophagitis · Japan | 4 | Completed | Mar 5, 2022 | 208 |
| NCT02388737Erosive Esophagitis · China, Korea, Republic of, Malaysia and more | 3 | Completed | Dec 24, 2018 | 703 |
| NCT02388724Erosive Esophagitis · China, Korea, Republic of, Malaysia and more | 3 | Completed | Jul 27, 2017 | 481 |
| NCT02141711Gastroesophageal Reflux · United Kingdom | 1 | Completed | Feb 2009 | 48 |
| NCT02141698Dose Finding Study | 1 | Completed | Feb 2008 | 73 |
| NCT02123953Dose Finding Study | 1 | Completed | Mar 2009 | 60 |
| NCT02123927Ascending Single Dose Study | 1 | Completed | Dec 2007 | 108 |
| NCT01630746Erosive Esophagitis · Japan | 3 | Completed | Sep 2013 | 19 |
| NCT01568398Stomach Ulcer · Japan | 3 | Completed | Aug 2013 | 27 |
| NCT01568385Stomach Ulcer · Japan | 3 | Completed | Sep 2013 | 30 |
| NCT01505127H. Pylori Infection · Japan | 3 | Completed | Jun 2013 | 650 |
| NCT01474369Non-erosive Gastroesophageal Reflux Disease · Japan | 3 | Completed | Feb 2013 | 827 |
| NCT01459367Erosive Esophagitis · Japan | 3 | Completed | Mar 2013 | 607 |
| NCT01456260Stomach Ulcer · Japan | 3 | Completed | 406 | |
| NCT01456247Stomach Ulcer · Japan | 3 | Completed | Oct 2013 | 439 |
| NCT01452776Erosive Esophagitis · Japan | 3 | Completed | Jul 2013 | 305 |
| NCT01452763Stomach Ulcer · Japan | 3 | Completed | Apr 2013 | 621 |
| NCT01452750Stomach Ulcer · Japan | 3 | Completed | Jun 2013 | 642 |
| NCT01452724Duodenal Ulcer · Japan | 3 | Completed | Feb 2013 | 372 |
| NCT01452711Stomach Ulcer · Japan | 3 | Completed | Dec 2012 | 482 |
| NCT01452698Erosive Esophagitis · Japan | 3 | Completed | Aug 2012 | 409 |
How it is read
Names in the registry
- “TAK-438”, 32 entries
- “Vonoprazan”, 20 entries
- “Vonoprazan (Reference)”, 1 entry
- “Vonoprazan Tablets”, 1 entry
- “VOQUEZNA® Tablets”, 1 entry
Conditions, from the studies’ own filings
- Esophagitis, 9 studies
- Stomach Ulcer, 9 studies
- Gastroesophageal Reflux, 7 studies
- Heartburn, 3 studies
- Duodenal Ulcer, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.